


PHARMACEUTICAL 2022

UroGen Pharma Ltd. Rank 408 of 466









PHARMACEUTICAL 2022

UroGen Pharma Ltd. Rank 408 of 466



The relative strengths and weaknesses of UroGen Pharma Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of UroGen Pharma Ltd. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 20% points. The greatest weakness of UroGen Pharma Ltd. is the variable Other Liabilities, reducing the Economic Capital Ratio by 119% points.

The company's Economic Capital Ratio, given in the ranking table, is -84%, being 161% points below the market average of 78%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 114,390 |
| Cost of Goods Sold | 5,157 |
| Intangible Assets | 0 |
| Liabilities, Current | 22,380 |
| Liabilities, Non-Current | 398 |
| Other Assets | 3,389 |
| Other Compr. Net Income | -296 |
| Other Expenses | 18,740 |
| Other Liabilities | 88,555 |
| Other Net Income | 212 |
| Other Revenues | 48,042 |
| Property and Equipment | 1,967 |
| Research and Development | 47,642 |
| Selling, General and Administrative Expense | 87,535 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 119,746 |
| Liabilities | 111,333 |
| Expenses | 159,074 |
| Revenues | 48,042 |
| Stockholders Equity | 8,413 |
| Net Income | -110,820 |
| Comprehensive Net Income | -110,968 |
| Economic Capital Ratio | -84% |

